Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data
暂无分享,去创建一个
Matt van de Rijn | David Huntsman | Anthony Magliocco | Dianne Miller | M. Rijn | D. Huntsman | B. Clarke | Dianne Miller | C. Gilks | A. Magliocco | Robin L Parker | M. Akbari | A. Coldman | C Blake Gilks | A. AlKushi | N. Makretsov | Abdulmohsen Alkushi | Blaise A Clarke | Majid Akbari | Nikita Makretsov | Peter Lim | Andrew Coldman | Robin Parker | P. Lim | D. Miller | Abdulmohsen Alkushi
[1] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[2] M. Sherman,et al. Uterine Serous Carcinoma A Morphologically Diverse Neoplasm With Unifying Clinicopathologic Features , 1992, The American journal of surgical pathology.
[3] R. Kurman,et al. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. , 1997, Verhandlungen der Deutschen Gesellschaft fur Pathologie.
[4] A. L. Nielsen,et al. Evaluation of the reproducibility of the revised 1988 international federation of gynecology and obstetrics grading system of endometrial cancers with special emphasis on nuclear grading , 1991, Cancer.
[5] H. Watari,et al. Bcl‐2 expression and prognosis of patients with endometrial carcinoma , 1998, International journal of cancer.
[6] R. Bast,et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. , 1991 .
[7] A. Lindgren,et al. Carcinoma of the endometrium: do the nuclear grade and DNA ploidy provide more prognostic information than do the FIGO and WHO classifications? , 1996, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[8] Matt van de Rijn,et al. Tissue Microarrays Are an Effective Quality Assurance Tool for Diagnostic Immunohistochemistry , 2002, Modern Pathology.
[9] N. Ordóñez. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. , 1998, The American journal of surgical pathology.
[10] G. Ball,et al. High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.
[11] M. Koshiyama,et al. Two kinds of endometrial neoplasia arising from different origins in the uterine corpus: comparison of p53 expression and sex steroid receptor status. , 2002, European journal of obstetrics, gynecology, and reproductive biology.
[12] S. Yoshida,et al. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. , 2003, Endocrine-related cancer.
[13] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[14] Carlos Caldas,et al. Molecular Classification of Breast Carcinomas Using Tissue Microarrays , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[15] M. Sherman. Theories of Endometrial Carcinogenesis: A Multidisciplinary Approach , 2000, Modern Pathology.
[16] A. García,et al. Molecular pathology of endometrial hyperplasia and carcinoma. , 2001, Human pathology.
[17] R. Tibshirani,et al. Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data , 2004, PLoS biology.
[18] Jaime Prat,et al. Prognostic parameters of endometrial carcinoma. , 2004, Human pathology.
[19] A. Dursun,et al. Angiogenesis, p53, and bcl‐2 Expression as Prognostic Indicators in Endometrial Cancer: Comparison with Traditional Clinicopathologic Variables , 2003, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[20] Michael Peacock,et al. Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data Identifies Prognostically Significant Groups of Breast Carcinoma , 2004, Clinical Cancer Research.
[21] H. Homesley,et al. Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. , 1993, Gynecologic oncology.
[22] A. Berchuck,et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] D. O'connor,et al. An analysis of two versus three grades for endometrial carcinoma. , 1999, Gynecologic oncology.
[24] S. Kalloger,et al. Description of a Novel System for Grading of Endometrial Carcinoma and Comparison With Existing Grading Systems , 2005, The American journal of surgical pathology.
[25] R. Slebos,et al. The frequency of p53, k‐ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma , 2000, Cancer.
[26] D. Botstein,et al. Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[27] Taylor Murray,et al. Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.
[28] R. Kurman,et al. A Binary Architectural Grading System for Uterine Endometrial Endometrioid Carcinoma Has Superior Reproducibility Compared With FIGO Grading and Identifies Subsets of Advance-Stage Tumors With Favorable and Unfavorable Prognosis , 2000, The American journal of surgical pathology.
[29] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[30] M. Rijn,et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray , 2003, Virchows Archiv.
[31] C. Gilks,et al. Markers of Proliferative Activity Are Predictors of Patient Outcome for Low-Grade Endometrioid Adenocarcinoma But Not Papillary Serous Carcinoma of Endometrium , 2002, Modern Pathology.
[32] C. Sotiriou,et al. Molecular classification of breast carcinomas by immunohistochemistry (IHC) using the tissue microarrays (TMA): new subtypes with clinical relevance? , 2004 .
[33] D. Huntsman,et al. Interpretation of p53 Immunoreactivity in Endometrial Carcinoma: Establishing a Clinically Relevant Cut-Off Level , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[34] M. Jacobsen,et al. Interobserver agreement for tumour type, grade of differentiation and stage in endometrial carcinomas , 1995, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[35] P. Roche,et al. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma. , 2000, Gynecologic oncology.
[36] C. Gilks,et al. Growth Factor Independence-1 Is Expressed in Primary Human Neuroendocrine Lung Carcinomas and Mediates the Differentiation of Murine Pulmonary Neuroendocrine Cells , 2004, Cancer Research.
[37] P. Schwartz,et al. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: Correlation between biochemical and immunohistochemical methods and survival. , 1990, American journal of clinical pathology.
[38] M. Carcangiu,et al. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. , 1992, Gynecologic oncology.
[39] W. van Putten,et al. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma , 2004, Cancer.
[40] B. Goff. Uterine papillary serous carcinoma: what have we learned over the past quarter century? , 2005, Gynecologic Oncology.
[41] E. Lerma,et al. Uterine papillary serous adenocarcinoma. A 10‐case study of p53 and c‐erbB‐2 expression and DNA content , 1994, Cancer.
[42] M. Rue,et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities , 2005, Modern Pathology.
[43] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[44] Peter Devilee,et al. Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2003 .
[45] D. Clarke-Pearson,et al. Overexpression of HER‐2/neu in endometrial cancer is associated with advanced stage disease , 1991, American journal of obstetrics and gynecology.
[46] J. V. Bokhman. Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.
[47] Ash A. Alizadeh,et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. , 2002, The American journal of pathology.
[48] E. Israels,et al. The Cell Cycle , 2007 .
[49] C Blake Gilks,et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. , 2002, American journal of clinical pathology.
[50] R. Kurman,et al. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A gynecologic oncology group study , 1995, Cancer.
[51] E. Siegel,et al. Amplification of c‐erbB2 oncogene , 2005, Cancer.
[52] A. Gown,et al. p63 Expression in Lung Carcinoma: A Tissue Microarray Study of 408 Cases , 2004, Applied immunohistochemistry & molecular morphology : AIMM.
[53] Daniel Birnbaum,et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. , 2005, Cancer research.
[54] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[55] B. Naylor,et al. The Uterine Corpus , 1992 .